Alnylam Pharmaceuticals, Inc.

ALNY

US02043Q1076

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 24/06/2025 BST			5-day change	1st Jan Change
325.00 ^USD	+3.79%		+5.28%	+38.12%

06-18	Alnylam Announces Promotion of Pushkal Garg as Executive Vice President and Chief Research and Development Officer	CI
06-09	Alnylam Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 09:20 AM

HC Wainwright Adjusts Price Target on Alnylam Pharmaceuticals to $400 From $395, Maintains Buy Rating

Published on 07/05/2024 at 14:12, updated on 07/05/2024 at 14:13

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Alnylam Pharmaceuticals, Inc.

Alnylam Announces Promotion of Pushkal Garg as Executive Vice President and Chief Research and Development Officer	06-18	CI
Alnylam Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 09:20 AM	06-09
Alnylam Gets EU Approval for RNAi Drug to Treat Transthyretin Amyloidosis With Cardiomyopathy	06-09	MT
Alnylam Receives European Commission Approval for AMVUTTRA®? for the Treatment of ATTR Amyloidosis with Cardiomyopathy	06-09	CI
Transcode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board	05-28	CI
Alnylam Pharmaceuticals Insider Sold Shares Worth $3,124,217, According to a Recent SEC Filing	05-19	MT
Alnylam Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 11:20 AM	05-14
Alnylam Pharmaceuticals, Inc. to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the Helios-B Phase 3 Study Results at Heart Failure 2025 Congress	05-12	CI
Alnylam To Share Progress Across Its Transthyretin Amyloidosis Franchise Including Additional Analyses Of The Helios-B Phase 3 Study Results At Heart Failure 2025 Congress	05-12	RE
UBS Adjusts Alnylam Pharmaceuticals Price Target to $349 From $331, Maintains Buy Rating	05-02	MT
Alnylam Q1 Non-GAAP Net Loss Narrows, Revenue Rises	05-01	MT
Alnylam Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 01, 2025	05-01
Alnylam Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-01	CI
Earnings Flash (ALNY) Alnylam Pharmaceuticals Posts Q1 Revenue $594.2M, vs. FactSet Est of $588.4M	05-01	MT
(ALNY) Alnylam Pharmaceuticals Sees Fiscal Year 2025 Revenue Range $2.05B - $2.25B	05-01	MT
Earnings Flash (ALNY) Alnylam Pharmaceuticals Reports Q1 Loss $-0.01 Per Share, vs. FactSet Est of $-0.38	05-01	MT
Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2025	05-01	CI
Alnylam's Transthyretin Amyloidosis Drug Gets Positive Opinion From European Medicines Agency	04-28	MT
Alnylam Receives Positive CHMP Opinion For Vutrisiran For The Treatment Of Attr Amyloidosis With Cardiomyopathy	04-28	RE
Alnylam Pharmaceuticals, Inc. Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy	04-28	CI
BofA Adjusts Price Target on Alnylam Pharmaceuticals to $328 From $325, Keeps Buy Rating	04-17	MT
Alnylam Pharmaceuticals, Inc. Presents at 24th Annual Needham Virtual Healthcare Conference, Apr-08-2025 11:45 AM	04-08
Alnylam Pharmaceuticals' Qfitlia Approved by FDA for Hemophilia A, B Treatment	03-31	MT
Alnylam Pharmaceuticals, Inc. Presents New Data from the HeliOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy At the American College of Cardiology's Annual Scientific Session 2025	03-29	CI
Fda Approves Alnylam Pharmaceuticals, Inc.'S Qfitlia? for the Treatment of Hemophilia A or B	03-28	CI

Chart Alnylam Pharmaceuticals, Inc.

Duration

Period

ALNY: Dynamic Chart

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. In addition, the Company develops Cemdisiran to treat complement-mediated diseases, Belcesiran for the treatment of alpha-1 liver disease, Elebsiran, Zilebesiran, ALN-APP, ALN-HSD, Fitusiran, and others.

Employees

2,230

Sector

Pharmaceuticals

Calendar

07-30 - Q2 2025 Earnings Release (Projected)

More about the company